To identify tumors harboring mutations in these genes, we probed the tumor lysates with monoclonal antibodies, which selectively recognize the G12V and G12D mutants of KRAS and the L858R mutant of EGFR69 (Fig. 8a). Here, KRAS is linked to neoplasm.